Together we will beat cancer

Donate

Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in Scotland

Three new treatment options made available for cancer patients in Scotland.

Read More

Three cancer drugs approved for NHS use in Scotland

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

Read More

Coming together for Zynlonta

How scientific expertise, funding and entrepreneurship came together for the development of an antibody-drug conjugate targeting lymphoma.

Read More

Scientists trial new way to boost CAR T-cell therapy

Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that ‘reboots’ a treatment for some people with blood cancer whose cancer starts to come back.

Read More

Transforming optimism: finding new ways to treat rare cancers

We spoke to Dr Kate Cwynarski, who led the Stand Up To Cancer-funded MARIETTA trial, a clinical trial which details a “potentially transforming” treatment for some patients with secondary CNS lymphoma.

Read More

Three new cancer drugs approved for NHS in Scotland

The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.

Read More

NHS patients among first to access new CAR T cell therapy for lymphoma

Lymphoma patients in England are among the first in the world to be offered new CAR T cell therapy.

Read More

Non-Hodgkin lymphoma treatment gets the green light for NHS use in England 

The National Institute for Health and Care Excellence has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma.

Read More

New treatment for rare blood cancer approved for NHS use in England

The National Institute for Health and Care Excellence (NICE) has approved the drug brentuximab vedotin on the NHS in England.

Read More

Targeted drug improves survival for children with non-Hodgkin lymphoma

New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma.

Read More